Annual financial statement
Page 1
\ (1) The Directors believe the presentation of 'adjusted net loss' provides the best measure to assess the performance of the Group. Adjusted net loss excludes certain non-cash or non-recurring items. Refer to the below table for a reconciliation from reported statutory net loss under Australian Accounting Standards measures. A$’000 Revenue from ordinary activities up 21% to 7,062 Loss from ordinary activities after tax attributable to members up (580%) to (204,436) Net loss for the period attributable to members up (574%) to (203,021) Adjusted(1) net loss for the period attributable to members down 7% to (32,934) 2026 2025 (1) Reconciliation of adjusted net loss for the period Notes $ $ Reported net loss for the period (203,020,956) (30,112,682) Add back: Non-cash Share Based Payment Expense (net of lapsed options) 5 (13,009,371) (2,730,244) Non-cash gain on remeasurement of contingent consideration liability 7,533,000 7,883,000 Non-cash remeasurement of financial debt instrument 3 (164,610,476) - Adjusted net loss for the period (32,934,109) (35,265,438) 30 June 2026 $ 30 June 2025 $ Net tangible assets/(liabilities) per ordinary security 0.17 (0.02) Appendix 4E 4DMedical Limited ABN 31 161 684 831 Results for Announcement to the Market Year ended: 30 June 2026 (previous corresponding period: Year ended 30 June 2025) 2. Commentary on results for the period Operating revenue for FY26 was $7.1 million, with gross margins exceeding 90%. Underlying SaaS revenue, representing Group operating revenue after deducting contractual true-up payments and non-core lease income, was up 23% vs FY25, driven by strong commercial momentum across B2B SaaS hospital and radiology partners, third party AI-distributors and global medical technology companies. During the financial year ended 30 June 2026, 4DMedical recognised a non-cash expense relating to the fair value measurement of the equity component of the Pro Medicus Loan of $164.6 million. Refer to Note 3 for further information. The Company’s adjusted(1) net loss for FY26 was $32.9 million, favourable 7% compared to FY25. A reconciliation of reported to adjusted net loss for the period is as follows: Appendix 4E 4DMedical Limited ABN 31 161 684 831 4. Control gained or lost over entities Not applicable. 5. Investments in associates and joint ventures Not applicable. 6. Dividend distribution & reinvestment plans No dividends have been paid or declared since the end of the previous financial year, nor do the directors recommend the declaration of a dividend. 7. Audit status This report is based on the Consolidated Financial Statements for the year ended 30 June 2026 which are in the process of being audited. 1. Statutory results for announcement to the market 3. Net tangible assets/(liabilities) per ordinary security
Page 2
Please refer to the attached unaudited condensed financial statements for the year ended 30 June 2026: • Consolidated statement of profit or loss and other comprehensive income • Consolidated statement of financial position • Consolidated statement of changes in equity • Consolidated statement of cashflows • Abbreviated notes to the consolidated financial statements The information set out above and in the attached condenses financial statements has been provided to the ASX in accordance with a resolution of the Board of Directors. Dr. Andreas Fouras Managing Director and Chief Executive Officer 28 August 2026 Carlton, VIC Appendix 4E 4DMedical Limited ABN 31 161 684 831
Page 3
Contents Consolidated Statement of Profit or Loss and Other Comprehensive Income 02 Consolidated Statement of Financial Position 03 Consolidated Statement of Changes in Equity 04 Consolidated Statement of Cash Flows 05 Abbreviated Notes to the Consolidated Financial Statements 06 1. Revenue and expenses 06 2. Intangible assets 09 3. Debt instrument 10 4. Issued capital and reserves 12 5. Share-based payments 14 6. Significant events after the reporting period 17 Consolidated Entity Disclosure Statement 18 Appen DIx 4e 2026 | 01
Page 4
Consolidated Statement of Profit or Loss and Other Comprehensive Income For the year ended 30 June 2026 Note 2026 $ 2025 $ Revenue 1.1 7,061,546 5,853,401 Cost of sales (440,082) (464,426) Gross income 6,621,464 5,388,975 Other income 1.3 7,534,039 10,631,191 Other gains – net 1.4 7,273,030 7,290,722 employee benefits expense 1.5 (39,242,111) (32,101,859) Other operating expenses 1.6 (19,436,408) (16,120,287) Remeasurement of financial debt instrument 3 (164,610,476) – Loss before interest, taxes, depreciation & amortisation (201,860,462) (24,911,258) Depreciation and amortisation expense (5,457,333) (5,326,060) net interest income 1.7 1,748,467 80,346 Loss before income tax (205,569,328) (30,156,972) Income tax benefit 1,133,419 87,118 Loss for the year (204,435,909) (30,069,854) Other comprehensive income/(loss) Other comprehensive gain/(loss) that may be reclassified to profit or loss in subsequent periods: exchange differences on translation of foreign operations 4.4 1,414,953 (42,828) Total comprehensive loss for the year (203,020,956) (30,112,682) Loss per share: Basic, loss for the year attributable to ordinary equity holders (0.03) (0.14) Diluted, loss for the year attributable to ordinary equity holders (0.03) (0.14) The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes. 02 | 4DMe DICAl
Page 5
Consolidated Statement of Financial Position As at 30 June 2026 Note 2026 $ 2025 $ Assets Current assets Cash and cash equivalents 277,954,095 6,878,735 Trade and other receivables 3,917,982 1,412,742 Research and development tax incentive receivable 5,538,520 6,022,697 Inventories 216,827 919,631 Other current assets 2,324,372 1,827,706 Total current assets 289,951,796 17,061,511 Non-current assets Intangible assets 2 68,451,587 70,238,748 property, plant and equipment 4,838,833 4,489,799 Right-of-use assets 2,089,841 2,976,749 Other non-current receivables 7,000 44,800 Total non-current assets 75,387,261 77,750,096 Total assets 365,339,057 94,811,607 Liabilities Current liabilities Trade and other payables 2,417,297 4,129,756 Contract liabilities 800,081 799,176 Government grants 2,007,166 3,620,124 lease liabilities 1,025,142 1,091,296 employee benefit liabilities 3,166,788 1,980,791 Deferred consideration – 7,633,500 Total current liabilities 9,416,474 19,254,643 Non-current liabilities Debt instrument 3 7,949,236 – Derivative financial instrument 3 169,073,027 – lease liabilities 2,191,603 3,216,745 Contract liabilities 325,139 525,161 employee benefit liabilities 347,027 278,491 Deferred tax liabilities 5,678,951 7,146,631 Other non-current liabilities 193,332 154,771 Total non-current liabilities 185,758,315 11,321,799 Total liabilities 195,174,789 30,576,442 Net assets 170,164,268 64,235,165 Equity Issued capital 4 544,379,864 239,969,742 Share-based payment reserve 4.3 11,311,417 6,771,480 Foreign currency translation reserve 4.4 1,015,997 (398,956) Accumulated losses (386,543,010) (182,107,101) Total equity 170,164,268 64,235,165 Total liabilities and equity 365,339,057 94,811,607 The above consolidated statement of financial position should be read in conjunction with the accompanying notes. Appen DIx 4e 2026 | 03
Page 6
Consolidated Statement of Changes in Equity For the year ended 30 June 2026 Issued capital (Note 4.2) $ Share-based payment reserve (Note 4.3) $ Foreign currency translation reserve (Note 4.4) $ Accumulated losses $ Total equity $ At 1 July 2025 239,969,742 6,771,480 (398,956) (182,107,101) 64,235,165 loss for the period – – – (204,435,909) (204,435,909) Other comprehensive loss – – 1,414,953 – 1,414,953 Total comprehensive loss for the period – – 1,414,953 (204,435,909) (203,020,956) Issue of share capital 233,000,005 – – – 233,000,005 Capital raising costs (13,197,841) – – – (12,714,177) Share-based payments expense during the year – 13,423,657 – – 13,423,657 Share-based payments expense during the year – options lapsed – (414,286) – – (414,286) exercise of options – proceeds received 76,138,523 – – – 75,654,860 Settlement of options – issued capital 5,435,822 (5,435,822) – – – Settlement of rights – issued capital 3,033,612 (3,033,612) – – – At 30 June 2026 544,379,864 11,311,417 1,015,997 (386,543,010) 170,164,268 Issued capital (Note 4.2) $ Share-based payment reserve (Note 4.3) $ Foreign currency translation reserve (Note 4.4) $ Accumulated losses $ Total equity $ At 1 July 2024 218,430,126 4,889,898 (356,128) (152,037,247) 70,926,649 loss for the period – – – (30,069,854) (30,069,854) Other comprehensive loss – – (42,828) – (42,828) Total comprehensive loss for the period – – (42,828) (30,069,854) (30,112,682) Issue of share capital 21,251,742 – – – 21,251,742 Capital raising costs (1,360,787) – – – (1,360,787) Share-based payments expense during the year – 3,968,844 – – 3,968,844 Share-based payments expense during the year – options lapsed – (1,238,601) – – (1,238,601) exercise of options – proceeds received 800,000 – – – 800,000 Settlement of options – issued capital 332,346 (332,346) – – – Settlement of rights – issued capital 516,315 (516,315) – – – At 30 June 2025 239,969,742 6,771,480 (398,956) (182,107,101) 64,235,165 The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes. 04 | 4DMeDICAl
Page 7
Consolidated Statement of Cash Flows For the year ended 30 June 2026 Note 2026 $ 2025 $ Operating activities Receipts from customers 5,688,391 5,388,440 p ayments to suppliers and employees (32,846,802) (33,613,039) Research costs (14,699,051) (14,840,124) Interest received 3,549,789 448,482 Interest and other costs of finance paid 1.7 (203,144) (255,075) Government grants and tax incentives 7,469,488 8,738,109 n et GST paid (233,611) (342,226) Net cash flows used in operating activities (31,274,940) (34,475,433) Investing activities Capitalisation of development costs to intangible assets (1,135,370) (1,064,212) p urchase of intangible assets (315,409) (197,425) p urchase of property, plant and equipment (949,826) (85,838) p roceeds from disposal of property, plant and equipment - 22,880 p ayments to acquire entities (25,219) (297,382) Net cash flows used in investing activities (2,425,824) (1,621,977) Financing activities p roceeds from issues of equity securities 4.2 233,037,805 13,903,355 p roceeds from exercise of options 4.2 76,138,523 800,000 Transaction costs related to issues of equity securities 4.2 (13,197,839) (1,360,787) p roceeds from borrowings 3 10,000,000 – Transaction costs related to loans and borrowings 3 (111,069) – p ayment of principal portion of lease liabilities (1,091,296) (972,567) Net cash flows from financing activities 304,776,124 12,370,001 net (decrease)/increase in cash and cash equivalents 271,075,360 (23,727,409) Cash and cash equivalents at the beginning of the period 6,878,735 30,606,144 Cash and cash equivalents at the end of the period 277,954,095 6,878,735 The above consolidated statement of cash flows should be read in conjunction with the accompanying notes. Appen DIx 4e 2026 | 05
Page 8
Abbreviated Notes to the Consolidated Financial Statements For the year ended 30 June 2026 1. Revenue and expenses 1.1 Revenue from contracts with customers Set out below is the disaggregation of the Group’s revenue from contracts with customers: 2026 $ 2025 $ Type of goods or service Software-as-a-Service (SaaS) 6,927,498 5,736,520 lease income 93,169 75,000 Ongoing support and maintenance 40,879 41,881 Total revenue from contracts with customers 7,061,546 5,853,401 Timing of revenue recognition Services transferred over time 5,492,506 4,824,143 Services transferred at a point in time 1,569,040 1,029,258 Total revenue from contracts with customers 7,061,546 5,853,401 Geographical markets United States of America 6,886,462 5,730,201 Australia 175,084 123,200 Total revenue from contracts with customers 7,061,546 5,853,401 1.2 Performance obligations • Software-as-a-Service (SaaS) The Group generates revenue from SaaS subscription arrangements and pay-per-session services. Revenue from SaaS subscription arrangements includes revenue from the provision of hosted software access, commercialisation rights and licence rights, together with related support, maintenance and other interdependent stand-ready services. These activities are highly integrated and are accounted for as a single performance obligation. Revenue is recognised over time as customers simultaneously receive and consume the benefits of access to the Group’s platform throughout the contract term. Revenue is recognised on a straight-line basis over the period of access as this best reflects the transfer of services to the customer. Revenue from pay-per-session arrangements is recognised at a point in time when the relevant service has been completed and the related output, including scan analysis, diagnostic outputs or reports, has been provided to the customer. At this point, control of the output has been transferred to the customer, and the Group has no remaining substantive performance obligations. Accordingly, subscription-based SaaS revenue is recognised over time, while transaction-based services are recognised at a point in time, reflecting the nature of the underlying performance obligations. • Lease income The Group provides hardware to customers under an operating lease model. The lease payments from operating leases are recognised as income on a straight-line basis over the lease term. • Ongoing support and maintenance Ongoing support and maintenance services are provided for a defined time period in which the customer has the ability to use the Group’s support team in relation to goods purchased by the customer. entitlement to this service is either considered over time or linked to output targets. payment is received in advance, and the revenue is recognised over the satisfaction period and commences from the date the related goods are delivered. 06 | 4DMe DICAl
Page 9
Abbreviated notes to the Consolidated Financial Statements continued Contract liabilities The transaction price allocated to the remaining performance obligations (unsatisfied or partially unsatisfied) as at 30 June are as follows: 2026 $ 2025 $ Within one year 800,081 799,176 More than one year 325,139 525,161 Total contract liabilities 1,125,220 1,324,337 The remaining performance obligations expected to be recognised in more than one year relate to the provision of software licences that are to be satisfied after 12 months from balance date. All the other remaining performance obligations are expected to be recognised within one year. The above table does not include deferred revenue relating to government grants. 1.3 Other income 2026 $ 2025 $ Government grants 2,869,653 5,428,231 Research and development (R&D) tax incentive 4,664,386 5,202,960 Total other income 7,534,039 10,631,191 1.4 Other gains – net 2026 $ 2025 $ net fair value gain on financial liabilities at FVTpl 7,533,000 7,883,000 Foreign exchange losses (259,970) (600,899) net gain on disposal of property, plant and equipment – 8,621 Total other gains – net 7,273,030 7,290,722 Appen DIx 4e 2026 | 07
Page 10
Abbreviated notes to the Consolidated Financial Statements continued 1.5 Employee benefits expense 2026 $ 2025 $ Wages and salaries 19,939,313 21,560,635 Other employee and directors’ benefits expenses 6,293,427 7,810,980 equity-settled share-based payments (note 5) 13,009,371 2,730,244 Total employee benefits expense 39,242,111 32,101,859 1.6 Other expenses 2026 $ 2025 $ legal, professional and consultant expenses 8,678,952 5,153,682 Computer expenses 3,858,680 3,931,391 Travel expenses 1,981,208 1,564,304 Sales and marketing expenses 1,694,186 1,619,351 General expenses 1,386,758 439,393 Occupancy and utilities expenses 1,013,949 1,081,071 Clinical trial expenses 326,635 391,532 Insurance expenses 295,919 427,602 Research and development expenses 144,413 852,354 Imbio integration expenses 55,709 659,607 Total other expenses 19,436,408 16,120,287 1.7 Net interest income 2026 $ 2025 $ Interest expense on debt instrument 2,522,856 – Interest expense on lease liabilities 196,228 246,418 Interest expense on insurance premium funding 6,916 8,656 Total finance costs 2,726,000 255,074 Interest income 4,474,467 335,420 Total finance income 4,474,467 335,420 Net interest income 1,748,467 80,346 08 | 4DMe DICAl
Page 11
Abbreviated notes to the Consolidated Financial Statements continued 2. Intangible assets Goodwill $ Software $ Development costs $ Trademark and Patents $ Other intangible assets $ Total $ Cost At 1 July 2024 42,712,533 24,903,975 5,832,424 1,830,451 657,551 75,936,934 Additions – – 1,064,212 202,030 – 1,266,242 Assets written off – – – (112,390) – (112,390) exchange differences – – – 7,269 7,098 14,367 At 30 June 2025 42,712,533 24,903,975 6,896,636 1,927,360 664,649 77,105,153 Cost At 1 July 2025 42,712,533 24,903,975 6,896,636 1,927,360 664,649 77,105,153 Additions – – 1,135,370 296,001 – 1,431,371 Assets written off – – – (68,001) – (68,001) exchange differences – – – (43,314) (29,603) (72,917) At 30 June 2026 42,712,533 24,903,975 8,032,006 2,112,046 635,046 78,395,606 Accumulated amortisation At 1 July 2024 – 911,958 1,968,081 520,146 362,215 3,762,400 Amortisation for the period – 1,723,105 1,263,625 34,738 85,590 3,107,058 exchange differences – (10,259) – 45,827 (38,621) (3,053) At 30 June 2025 – 2,624,804 3,231,706 600,711 409,184 6,866,405 Accumulated amortisation At 1 July 2025 – 2,624,804 3,231,706 600,711 409,184 6,866,405 Amortisation for the period – 1,644,892 1,482,962 50,360 81,735 3,259,949 exchange differences – (143,279) – 20,190 (59,246) (182,336) At 30 June 2026 – 4,126,417 4,714,668 671,261 431,673 9,944,019 Net book value at 30 June 2025 42,712,533 22,279,171 3,664,930 1,326,649 255,465 70,238,748 Net book value at 30 June 2026 42,712,533 20,777,558 3,317,338 1,440,785 203,373 68,451,587 Goodwill impairment testing Goodwill is allocated to a single cash-generating unit (CGU), consistent with the Group’s one operating segment. The recoverable amount of the CGU is based on value-in-use calculations using cash flow projections from financial forecasts approved by the Board for the 12 months immediately following the reporting date, and cash flows beyond 12 months extrapolated through a five-year outlook. The assumptions used for the current reporting period may differ from the assumptions in the past or next reporting period as internal and external circumstances and expectations change. The Group has applied the assumptions below in the 30 June 2026 calculation of value-in-use. Appen DIx 4e 2026 | 09
Page 12
Abbreviated notes to the Consolidated Financial Statements continued Key assumptions and sensitivity analysis The calculation of value-in-use is most sensitive to the following assumptions: • Revenue growth in the outlook period: 67%-240%; • employee expenses growth in the outlook period: 5-10%; • Other operating expenses growth in the outlook period: 5-15%; • Discount rate (pre-tax): 18.1%; and • Terminal growth rate of 5%. The discount rate represents the current market assessment of the risks specific to the operating sector, taking into consideration the time value of money and the individual risks of the underlying assets that have been incorporated within the cash flow estimates. The discount rate calculation is based on the specific circumstances of the Group and is derived from its weighed average cost of capital (WACC). The WACC takes into account both debt and equity. The cost of equity is derived from the expected return on investment by the Group’s investors. The cost of debt is based on management’s assessment of an applicable risk-free rate plus a Group-specific risk premium. The Directors have considered the sensitivity of the impairment assessments to a reasonably possible change in the above key assumptions. Holding all other parameters constant, the following sensitivities would likely result in an impairment when viewed in isolation: • Operating Revenue decreasing by more than 36.8% • Discount rate (pre-tax), or WACC, increased by more than 29.9 percentage points In its impairment review, Directors have concluded that no impairment is required to the carrying amount of goodwill as at 30 June 2026. 3. Debt instrument Background In July 2025, 4DMedical entered into a secured facility agreement with pro Medicus limited (ASx:pMe, “pMe”), a global leader in medical imaging software and solutions, to provide 4DMedical with $10.0 million in strategic funding to accelerate commercialisation activities across the Company’s product portfolio. Material terms of the Facility Agreement The material terms of the Facility Agreement are as follows: • Borrower: 4DMedical limited; • Guarantor: 4DMedical limited and its Australian subsidiaries, and at pMe’s request, any other subsidiary of the Borrower; • Facility limit: AU$ 10,000,000; • Cash received: AU$ 9,888,931 after deducting pMe’s expenses relating to the transaction; • Maturity: Two (2) years, payable in August 2027; • early repayment: 4DMedical limited can opt to repay the facility earlier than the maturity date upon receipt of agreement from pMe; • Interest on facility: 12.5% over the maturity period; and • Security: All assets of the Borrower and Guarantor, including specific security over certain Intellectual property assets. 10 | 4DMe DICAl
Page 13
Abbreviated notes to the Consolidated Financial Statements continued Repayment terms: Cash component At maturity, 4DMedical will pay pMe the following: • Cash equal to the higher of: (i) $12.5 million; and (ii) $10.0 million x (4Dx 10-day VWAp at maturity)/(4Dx 10-day VWAp at execution), capped at $20.0 million. Repayment terms: Non-cash equity component (Derivative Financial Instrument) At maturity, 4DMedical will issue pMe equity in the Company as follows: • 4Dx shares equal to: ($10.0 million x (4Dx 10-day VWAp at maturity/4Dx 10-day VWAp at execution) – $20.0 million)/4Dx 10-day VWAp at maturity. In July 2025, the Company issued the capped amount of 40,000,000 4Dx shares in accordance with the Facility Agreement under its listing Rule 7.1A capacity, subject to the relevant VWAp performance conditions being satisfied. These shares are held in escrow and will be issued to pMe following these performance conditions being met in line with the Facility Agreement, upon maturity. Carrying value of Debt Instrument and associated Derivative Financial Instrument: Key judgements and accounting estimates 1. Debt Instrument: • As per the Facility Agreement, the Company will repay at least $12.5 million in cash upon maturity; • The 10-day VWAp on 31 July 2025, the date of the Facility Agreement, was $0.2494; • The Company is forecasting to repay the maximum capped $20.0 million cash repayment as it is expected the 10-day VWAp at maturity to be in the range to trigger the maximum cash repayment. The difference between the principal & Interest cash payment of $12.5 million, and maximum cash repayment of $20.0 million, is recognised as a Derivative Financial Instrument (refer to below); and • The carrying value of $7.9 million as at 30 June 2026 represents the discounted value of the debt instrument, calculated using an effective interest rate measured as at 30 June 2026. 2. Derivative Financial Instrument (non-cash equity component) • The Company used a Monte-Carlo simulation to value the derivative liability. This involves using a Geometric-Brownian Motion process to simulate 100,000 different stock price paths and the resulting likely payoff to holders under each scenario. The average of the present value of the total payoff in each scenario is used to obtain a fair value estimate. • Assumptions made to simulate the 4Dx stock price path include: – 4Dx’s stock price is lognormally distributed (i.e. no negative values) with a starting stock price of $0.24 on 31 July 2025; – Annual expected return of 4.5% equal to the risk-free rate (Australian government two-year bond rate on 30 June 2026), in line with AASB2 guidance; and – Daily random up/down movements generated from a standard normal distribution and scaled by the stock’s volatility, being 133.1% annual volatility over the past 1-year, in line with AASB2 guidance. • Accordingly, after simulating the share price path 100,000 times, the average present value of the derivative liability, being a non-cash unrealised fair value measurement recognised on the Balance Sheet as at 30 June 2026, was $169,073,027. • The Company will revalue this financial liability at each balancing date until maturity, based on the daily movement in 4DMedical’s share price, using the same valuation methodology, with changes in the fair value recognised through the consolidated statement of profit or loss and other comprehensive income. • The Company has no intention to repay the facility prior to maturity, hence the non-Current liability classification on the Balance Sheet as at 30 June 2026. Appen DIx 4e 2026 | 11
Page 14
Abbreviated notes to the Consolidated Financial Statements continued 4. Issued capital and reserves 30 June 2026 $ 30 June 2025 $ Ordinary shares 544,379,864 239,969,742 41 Terms and conditions of ordinary shares Fully paid ordinary shares carry one vote per share and carry the right to dividends. Fully paid ordinary shares have no par value. 4.2 Movement in ordinary shares on issue No. of shares $ As at 1 July 2024 410,394,665 218,430,126 Issued shares 51,531,262 21,251,742 e xercise of options – proceeds received 2,000,000 800,000 Conversion of options to issued capital 670,283 332,346 Conversion of rights to issued capital 944,264 516,315 Transaction costs relating to shares issued – (1,360,787) As at 30 June 2025 465,540,474 239,969,742 No. of shares $ As at 1 July 2025 465,540,474 239,969,742 Issued shares 34,944,046 233,000,005 e xercise of options – proceeds received 81,705,257 76,138,523 Conversion of options to issued capital 13,647,183 5,435,822 Conversion of rights to issued capital 1,722,161 3,033,612 Transaction costs relating to shares issued - (13,197,841) As at 30 June 2026 597,559,121 544,379,864 In January 2026, 4DMedical completed a $150.0 million single-tranche institutional placement at an issue price of $3.80 per share. The key details are as follows: • The institutional placement was comprised of a $79.1 million placement of new shares (“placement”) and a $70.9 million sale of existing shares on issue (“Block Trade”); • The placement will result in the issue of 20,806,185 shares (representing 3.86% dilution) at $3.80 per share within the Company’s existing placement capacity under ASx listing Rule 7.1; and • The 18,667,500 Block Trade shares were previously issued to Alpha Investment partners (“Alpha”) as collateral pursuant to a funding facility entered into between the Company and Alpha, as announced to market on 28 June 2024. These shares were repurposed to be issued as part of the institutional placement. In March 2026, 4DMedical completed an $83.0 million private placement at an issue price of $5.90 per share, following significant inbound interest from institutions looking to invest in the Company. The key details are as follows: • The placement raised $83.0 million (before costs), issuing 14,067,797 new, fully paid ordinary 4DMedical shares (representing 2.45% dilution), utilising the Company’s available placement capacity under ASx listing Rule 7.1. Transaction costs associated with the capital raised totalled $12.7 million. 12 | 4DMe DICAl
Page 15
Abbreviated notes to the Consolidated Financial Statements continued 4.3 Share-Based Payment Reserve The share-based payment reserve comprises of the value of the employee, non-employee and Director share plans that were granted during the current and previous financial years. The balance represents the fair value of options vested but not exercised, and unvested options. The movement of this reserve year-on-year is itemised in the Statement of Changes in equity. 4.4 Foreign Currency Translation Reserve The foreign currency translation reserve is used to record exchange differences arising from translation of financial statements of foreign subsidiaries. The movement of this reserve year-on-year is itemised in the Statement of Changes in equity. Appen DIx 4e 2026 | 13
Page 16
Abbreviated notes to the Consolidated Financial Statements continued 5. Share-based payments During the year ended 30 June 2026, certain employees (including KMp) were granted 17,223,251 options (FY25: 11,524,223) and 1,200,299 rights (FY25: 1,922,588) under the 4DMedical long-Term Incentive plan. 13,647,183 shares from the conversion of options (FY25: 2,670,283) and 1,722,161 shares from the conversion of rights (FY25: 944,264) were issued during the financial year. There are 15,433,531 options and 5,000 rights that were granted during the financial year but not yet vested under the long-Term Incentive plan as at 30 June 2025 (FY25: 7,328,450 and 1,200,000 respectively). The Group had the following share-based payment arrangements as at 30 June 2026: Plan Reference Date of grant On Issue as at 1 July 2025 Issued during FY26 Lapsed during FY26 Exer- cised during FY26 Balance as at 30 June 2026 Vested not exer- cised Un- vested Vesting conditions 2016 Options Offer (Other) 15/12/2016 3,280,018 – – – 3,280,018 3,280,018 – 50% to vest on/after 15 January 2017; and 50% on/after 30 June 2017 2017 Fundraiser’s Offer 01/03/2017 6,400,000 – – 4,266,667 2,133,333 2,133,333 – Vesting is subject to the Fundraising Hurdle 2017 Options USA Offer 25/08/2017 22,157 – – – 22,157 22,157 – 50% on 1 July 2018 and 50% on 30 June 2019 2019 USA Options Incentive Offer 08/06/2018 12,826 – – – 12,826 12,826 – 50% on 1 July 2019 and 50% on 30 June 2020 FY22B long-Term Incentive plan (Other) 01/09/2021 701,719 – 701,719 – – – – Must remain an employee for a period from 1 July 2021 until 30 June 2024 FY22C long-Term Incentive plan 20/05/2022 636,576 – 636,576 – – – – Based on the Australian Revenue generated by the Company, with number of options vested at each Revenue Milestone FY23B long-Term Incentive plan 26/08/2022 715,748 – – 715,748 – – – Complete three years’ service from the grant date FY23C long-Term Incentive plan 18/11/2022 1,850,914 – – 1,850,914 – – – Must remain an employee for a period from 1 July 2022 until 30 June 2025 FY23A long-Term Incentive plan 23/11/2022 2,291,286 – – 2,291,286 – – – Must remain an employee for a continuous period from grant date until 1 July 2025 FY24 AU Sales Incentive Options2 28/07/2023 16,088 – – 16,088 – – – nil FY23 long-Term Incentive plan 15/09/2023 469,303 – – 469,303 – – – Must remain an employee for a continuous period from grant date until 01 December 2025 & 03 April 2026 respectively F Y23 Shor t-Term Incentive plan (1/2) 19/09/2023 88,837 – – 88,837 – – – nil FY24 long-Term Incentive plan (1/2) 22/09/2023 2,921,022 – – – 2,921,022 – 2,921,022 Must remain an employee for a continuous period from grant date until 1 July 2026 14 | 4DMe DICAl
Page 17
Abbreviated notes to the Consolidated Financial Statements continued Plan Reference Date of grant On Issue as at 1 July 2025 Issued during FY26 Lapsed during FY26 Exer- cised during FY26 Balance as at 30 June 2026 Vested not exer- cised Un- vested Vesting conditions FY24 long-Term Incentive plan – CeO 03/11/2023 1,306,100 – – – 1,306,100 – 1,306,100 nil FY24 long-Term Incentive plan (2/2) 13/03/2024 1,648,803 – – – 1,648,803 – 1,648,803 Must remain an employee for a continuous period from grant date until 1 July 2026 F Y23 Shor t-Term Incentive plan (2/2)2 13/03/2024 24,500 – – 24,500 – – – nil FY24 Options2 19/03/2024 30,000 – – 20,000 10,000 10,000 – nil FY25 long-Term Incentive plan 18/08/2024 4,317,882 – 56,250 4,261,632 – 4,261,632 Must remain an employee for a continuous period from grant date until 1 July 2027 F Y24 Shor t-Term Incentive plan2 28/10/2024 242,594 – 125,236 117,358 75,878 41,480 nil FY25 long Term Incentive plan – CeO 21/11/2024 775,339 – – 775,339 – 775,339 Must remain an employee for a continuous period from grant date until 30 June 2027 FY25 Incentive Options2 10/01/2025 4,249,999 – 2,433,335 1,816,664 316,668 1,499,996 Specific performance hurdles1 FY25 Incentive Rights2 10/01/2025 1,200,000 – 400,001 799,999 – 799,999 Specific performance hurdles1 FY25 Retention RSUs2 15/04/2025 126,861 – 126,861 – – – nil FY26 Retention RSUs2 28/07/2025 5,000 – – 5,000 – 5,000 nil FY26 Incentive Options2 03/09/2025 59,638 – 59,638 – – – nil FY26 long-Term Incentive plan 04/09/2025 9,004,400 – – 9,004,400 – 9,004,400 Must remain an employee for a continuous period from the grant date until 1 July 2028 FY26 long-Term Incentive plan 01/10/2025 1,860,856 – – 1,860,856 1,860,856 Must remain an employee for a continuous period from the grant date until 1 July 2028 FY26 Incentive Options2 01/10/2025 16,122 16,122 – – – nil FY25 Short-Term Incentive plan2 01/10/2025 1,513,845 – 1,336,302 177,543 177,543 – nil FY26 Director Options2 15/12/2025 1,395,414 – 1,072,256 323,158 323,158 – nil FY26 long-Term Incentive plan – CeO 15/12/2025 4,568,275 – – 4,568,275 – 4,568,275 Must remain an employee for a continuous period from grant date until 30 June 2028 Total 33,328,572 18,423,550 1,338,295 15,369,344 35,044,483 6,351,581 28,692,902 1. The vesting conditions of the FY25 Incentive Options and Rights include: a) share price targets, b) CT:VQ™ revenue targets, and c) investment targets, as well as continuous employment up to the vesting date. 2. Indicates zero-exercise price options related to short-term benefits, in lieu of cash payments, valued at the share price on grant date. Appen DIx 4e 2026 | 15
Page 18
Abbreviated notes to the Consolidated Financial Statements continued Movements during the year The cost recognised for employee and Directors’ services received during the year and remunerated by equity-settled share-based payment transactions is shown in the following table: 30 June 2026 $ 30 June 2025 $ Recognised in employee and directors’ benefits expense (note 1.5) 13,009,371 2,730,244 Total net expense arising from share-based payment transactions 13,009,371 2,730,244 The following table illustrates the number of, and movements in, options during the year: 2026 No. of options 2025 No. of options Outstanding at 1 July 32,001,711 32,751,931 Granted during the year 17,223,251 11,524,223 Forfeited/lapsed during the year (1,338,295) (9,604,160) n et settled and converted to issued capital during the year (13,647,183) (2,670,283) Outstanding at 30 June 34,239,484 32,001,711 Vested and exercisable at 30 June 6,351,581 12,833,509 The following table illustrates the number of, and movements in, rights during the year: 2026 No. of rights 2025 No. of rights Outstanding at 1 July 1,326,861 348,537 Granted during the year 1,200,299 1,922,588 n et settled and converted to issued capital during the year (1,722,161) (944,264) Outstanding at 30 June 804,999 1,326,861 Vested and exercisable at 30 June – 348,537 The weighted average remaining contractual life for the options and rights outstanding as at 30 June 2026 was 3.55 years (FY25: 2.49 years). The weighted average fair value of all options and rights granted during the year was $1.70 (FY25: $0.45). The range of exercise prices for options outstanding at the end of the year was $0.28 to $1.60 (FY25: $0.36 to $2.60). The following tables list the inputs to the models used for the plans for the year ended in 30 June 2026 and 30 June 2025 respectively: 2026 2025 Option plans Right plans Option plans Right plans Weighted average fair values at the measurement ($) 1.70 – 0.45 0.00 expected volatility (%) 118 – 86 – Risk-free interest rate (%) 3.53-4.17 – 3.53-3.55 – expected life of share options (years) 1.00-4.54 – 1.00-4.00 – Weighted average share price ($) 1.64 2.33 0.56 0.48 Model used Black-Scholes n/A Black-Scholes n/A The fair value at grant date of the performance rights issued with non-market performance conditions is the share price at grant date. The expected life of the options is based on historical data and current expectations, and is not necessarily indicative of exercise patterns that may occur. The expected volatility reflects the assumptions that historical volatility over a period similar to the life of the options is indicative of future trends, which may not necessarily be the actual outcome. 16 | 4DMe DICAl
Page 19
Abbreviated notes to the Consolidated Financial Statements continued 6. Significant events after the reporting period • In June 2026, 4DMedical entered into a binding agreement to acquire 100% of the issued capital in contextflow GmbH, an Austrian-based medical technology company specialising in lung cancer screening and advanced AI-driven thoracic imaging. Total upfront consideration is €11.42 million (approximately AU$18.56 million) in cash and 56,235 ordinary 4Dx shares. Subject to shareholder approval, contingent consideration of up to 2,589,247 4Dx options will be issued and vest periodically on the achievement of key milestones, by certain deadlines. Between signing and completion, 4DMedical loaned contextflow €0.6 million. On 12 August 2026, following approval from the Austrian Federal Ministry of economy, energy and Tourism, the acquisition was completed. • In July 2026, 4DMedical was the lead investor in RevealDx’s Series A financing, investing US$3.4 million (approximately AU$4.9 million) for a fully diluted interest of 10%, together with a seat on the RevealDx board and a right of first negotiation over any future sale of the company. In connection with the investment, 4DMedical and RevealDx have agreed terms for a Cooperation and Distribution Agreement under which 4DMedical is appointed distributor of RevealAI-lung, on a standalone basis and as part of the integrated solution with contextflow’s software. 4DMedical holds exclusive distribution rights across europe, Australia and new Zealand, and non-exclusive rights in the United States. The agreement is effective immediately and replaces contextflow’s prior distribution arrangement with RevealDx, consolidating the two companies’ complementary products under a single commercial channel controlled by 4DMedical. Appen DIx 4e 2026 | 17
Page 20
Consolidated Entity Disclosure Statement As required by the Treasury laws Amendment (Making Multinationals Pay Their Fair Share – Integrity and Transparency) Act 2024, the following provides information about the subsidiaries included in the consolidated financial statements of 4DMedical limited as at 30 June 2026. Name of Entity Type of Entity Country of incorporation Country of tax domicile Equity interest % Imbio Inc. Body Corporate USA USA 100 4DMedical USA Inc. Body Corporate USA USA 100 4DMedical R&D Inc. Body Corporate USA USA 100 Australian lung Health Initiative pty ltd Body Corporate Australia Australia 100 4DMedical USA HoldCo llC. Body Corporate USA USA 100 4DMedical employee Share Trust (Trustee: pacific Custodians pty ltd) Trust Australia Australia 100 4DMedical R&D pty ltd Body Corporate Australia Australia 100 4DMedical europe HoldCo GmbH Body Corporate Austria Austria 100 4DMedical nZ limited Body Corporate new Zealand new Zealand 100 18 | 4DMe DICAl